This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
ausbiz speaks with Race CEO on the Phase 1 trial ethics approval
Race CEO and Managing Director Dr Daniel Tillett speaks with ausbiz’s Juliette Saly about the ethics approval for the RC220 bisantrene Phase 1 clinical trial.
Watch the full video via this link.